靶向CSF1/CSF1R轴:恶性脑膜瘤的潜在治疗策略
恶性脑膜瘤缺乏有效治疗,本研究基于人脑膜瘤中M2巨噬细胞富集的现象,在新型免疫健全小鼠模型(MGS1)中采用抗CSF1/CSF1R单克隆抗体靶向巨噬细胞调控轴。结果显示该治疗可抑制肿瘤生长,伴随髓系细胞重编程而对T细胞影响有限;患者血浆CSF1水平显著升高,肿瘤微环境中CD163+巨噬细胞高表达CSF1R。提示抗CSF1/CSF1R抗体可能是恶性脑膜瘤的有效免疫治疗策略。
要点
- 人脑膜瘤富含免疫抑制性髓系细胞,M2巨噬细胞为最常见免疫细胞类型。
- 抗CSF1/CSF1R单抗在MGS1模型中抑制肿瘤生长,而抗PD-1单抗无效。
- 治疗引起肿瘤微环境髓系细胞重编程,对T细胞影响有限。
核心结论
- 抗CSF1/CSF1R抗体治疗可能是恶性脑膜瘤的有效 normalization 癌症免疫治疗策略。
研究设计与样本
- 使用CIBERSORTx分析人脑膜瘤22种免疫亚群比例,并在新型免疫健全小鼠恶性脑膜瘤模型(MGS1)中使用抗CSF1或CSF1R单克隆抗体治疗。
- 采用RNA测序和质谱流式技术分析肿瘤微环境基因表达及免疫亚群变化。
- 通过ELISA检测患者血浆CSF1水平,多重定量免疫荧光检测人脑膜瘤组织芯片中CSF1R表达。
主要发现
- 人脑膜瘤高度富集免疫抑制性髓系细胞。
- MGS1模型重现人脑膜瘤微环境特征:髓系细胞丰富、浸润T细胞稀少、PD-L1低表达。
- 抗CSF1/CSF1R单抗治疗可消除小鼠脑膜瘤生长,而抗PD-1单抗无效。
- RNA-seq和质谱流式显示治疗引起髓系细胞重编程,对T细胞影响有限。
- 人患者血浆CSF1水平显著升高,肿瘤微环境中CD163+巨噬细胞高表达CSF1R。
临床怎么用
- 对于恶性脑膜瘤,靶向CSF1/CSF1R轴可能成为新的免疫治疗方向,尤其针对M2巨噬细胞富集的肿瘤微环境。
- 患者血浆CSF1水平和肿瘤CD163+巨噬细胞CSF1R表达可能作为潜在生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignant meningiomas are fatal and lack effective therapy. As M2 macrophages are the most prevalent immune cell type in human meningiomas, we hypothesized that normalizing this immunosuppressive population would be an effective treatment strategy. METHODS: We used CIBERSORTx to examine the proportions of 22 immune subsets in human meningiomas. We targeted the colony-stimulating factor 1 (CSF1) or CSF1 receptor (CSF1R) axis, an important regulator of macrophage phenotype, using monoclonal antibodies (mAbs) in a novel immunocompetent murine model (MGS1) for malignant meningioma. RNA sequencing (RNA-seq) was performed to identify changes in gene expression in the tumor microenvironment (TME). Mass cytometry was used to delineate changes in immune subsets after treatment. We measured patients' plasma CSF1 levels using ELISA and CSF1R expression using multiplex quantitative immunofluorescence in a human meningioma tissue microarray. RESULTS: Human meningiomas are heavily enriched for immunosuppressive myeloid cells. MGS1 recapitulates the TME of human meningiomas, including an abundance of myeloid cells, a paucity of infiltrating T cells, and low programmed death ligand 1 (PD-L1) expression. Treatment of murine meningiomas with anti-CSF1/CSF1R, but not programmed cell death receptor 1 (PD-1), mAbs abrogate tumor growth. RNA-seq and mass cytometry analyses reveal a myeloid cell reprogramming with limited effect on T cells in the TME. CSF1 plasma levels are significantly elevated in human patients, and CSF1R is highly expressed on CD163+ macrophages within the human TME. CONCLUSION: Our findings suggest that anti-CSF1/CSF1R antibody treatment may be an effective normalization cancer immunotherapy for malignant meningiomas.
引用
- Yeung J, Yaghoobi V, Miyagishima D, et al. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro Oncol. 2021. PMID: 33914067. doi:10.1093/neuonc/noab075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。